user

Extended Interval Dosing of Ocrelizumab in Patients with Multiple Sclerosis Is Not Associated with Meaningful Differences in Disease Activity

被引：0
|
作者：
Rjeily, N. Bou [1 ]
Fitzgerald, K. C. [1 ]
Mowry, E. M. [1 ]
机构：
[1] Johns Hopkins Univ, Neurol, Baltimore, MD USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P164
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [21] Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience
    Nasello, Martina
    Zancan, Valeria
    Rinaldi, Virginia
    Marrone, Antonio
    Renie, Roberta
    Diamant, Selene
    Marconi, Martina
    Le Mura, Lorenzo
    Salvetti, Marco
    Buscarinu, Maria Chiara
    Bellucci, Gianmarco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (10)
  • [22] Ocrelizumab extended interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience
    Guerrieri, S.
    Nozzolillo, A.
    Zanetta, C.
    Genchi, A.
    Azzimonti, M.
    Gattuso, I.
    Filippi, M.
    Moiola, L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 846 - 847
  • [23] EXTENDED INTERVAL DOSING OF OCRELIZUMAB REDUCES RISK OF DEVELOPING HYPOGAMMAGLOBULINAEMIA
    Allen, Christopher
    Russell, Melanie
    Pendlebury, Jessica
    Vollmer, Brandi
    Moswela, Olivia
    Raza, Pranee-Ta
    Garjani, Afagh
    Abdel-Fahim, Rasha
    Tallantyre, Emma
    Evangelou, Nikos
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [24] Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience
    Guerrieri, Simone
    Bucca, Chiara
    Nozzolillo, Agostino
    Genchi, Angela
    Zanetta, Chiara
    Cetta, Ilaria
    Rugarli, Giulia
    Gattuso, Irene
    Azzimonti, Matteo
    Rocca, Maria Assunta
    Moiola, Lucia
    Filippi, Massimo
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (09) : 2859 - 2864
  • [25] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, E.
    Schoof, L.
    Hogenboom, L.
    Wessels, M.
    van Ruyven, P.
    van Samkar, A.
    Mostert, J.
    van Kempen, Z.
    van Oosten, B. W.
    Wokke, B. H.
    Tallantyre, E.
    Myhr, K. M.
    Torkildsen, O.
    Killestein, J.
    Smets, I.
    Strijbis, E.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [26] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, Eline
    Schoof, Lisa
    Hogenboom, Laura
    Wessels, Mark
    van Ruyven, Paula
    van Samkar, Anusha
    Mostert, Jop
    van Kempen, Zoe
    van Oosten, Bob
    Wokke, Beatrijs
    Tallantyre, Emma
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    Killestein, Joep
    Smets, Ide
    Strijbis, Eva
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1063 - 1064
  • [27] Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab
    Mancinelli, Chiara Rosa
    Scarpazza, Cristina
    Cordioli, Cinzia
    De Rossi, Nicola
    Rasia, Sarah
    Turrini, Maria Vittoria
    Capra, Ruggero
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) : 790 - 794
  • [28] Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis
    Moccia, Marcello
    Loperto, Ilaria
    Santoni, Laura
    Masera, Silvia
    Affinito, Giuseppina
    Carotenuto, Antonio
    Lanzillo, Roberta
    Triassi, Maria
    Morra, Vincenzo Brescia
    Palladino, Raffaele
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2022, 12 (03) : 109 - 116
  • [29] Personalized extended interval dosing of natalizumab in multiple sclerosis: a prospective multicenter trial
    van Kempen, Z.
    Hoogervorst, E.
    Kalkers, N.
    Mostert, J.
    Lissenberg-Witte, B.
    de Vries, A.
    ten Brinke, A.
    van Oosten, B.
    Barkhof, F.
    Wattjes, M.
    Teunissen, C.
    Uitdehaag, B.
    Rispens, T.
    Killestein, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 735 - 736
  • [30] Long-term effectiveness of extended interval dosing of natalizumab in multiple sclerosis
    Ryerson, L. Zhovtis
    Lee, S.
    Bacon, T.
    Toth, E.
    Chinea, R.
    Gragui, D.
    Kister, I.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 358 - 359
12345